Pfizer Inc. (PFE) fair value analysis
S&P 500 · Updated 2026-10-19
PFE price how computed
Forward Fair Value verdict
OvervaluedPFE is trading at more than a 25% premium to estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $28.28
- Sector
- Healthcare
- 12-month range
- $23.67–$29.58
- Market cap
- $161B
- From 52-week high
- -4.4%
- Shares outstanding
- 5.7B
- Rank in Healthcare by discount to fair value
- #84 of 108
Last price is our 2026-10-19 weekly price; the chart runs through 2026-10-16.
Pfizer Inc. is a pharmaceutical and biotechnology company that develops, manufactures, and distributes prescription medications, vaccines, and consumer healthcare products across multiple therapeutic areas including oncology, immunology, cardiology, and infectious diseases. The company operates globally with research, manufacturing, and distribution facilities across North America, Europe, Asia, and other regions worldwide.
PFE currently ranks #84 of 108 Healthcare stocks by discount to fair value. It has screened as Overvalued for 14 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $161B
- P/E (trailing)
- 9x
- Revenue (TTM)
- $63.7B
- Net margin
- 6.8%
- EPS (TTM)
- $3.05
- Gross margin
- 72.8%
- Debt / equity
- 0.74
- Revenue growth (3-yr avg)
- 3.8%
- Shares outstanding
- 5.7B
Derived indicators how computed
- Quality grade
- C
- Margin trend
- Expanding
- 52-week position
- The top quarter of its range
- DCF cross-check
- Overvalued
Technicals how computed
- RSI (14-day)
- 73 · overbought
- 50-day average
- $27.97
- 200-day average
- $26.56
- Moving-average state
- 50-day above 200-day (golden cross state); price above both averages
Dividends how computed
- Paid, last 12 months
- $1.72 per share (4 payments)
- Yield on last price
- 6.08%
- Consecutive years of increases
- 15
- Next ex-dividend date
- 2026-11-06
- Last payment date
- 2026-09-01
Earnings how computed
- Next earnings report
- 2026-11-03 (pre-market)
- Last 8 quarters vs consensus
- 8 beat, 0 missed
- Quarter by quarter
- 2026-06 ▲ beat (+13.2%)
2026-03 ▲ beat (+4.2%)
2025-12 ▲ beat (+15.8%)
2025-09 ▲ beat (+38.1%)
2025-06 ▲ beat (+36.8%)
2025-03 ▲ beat (+37.3%)
2024-12 ▲ beat (+37.0%)
2024-09 ▲ beat (+73.8%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 10 buy · 16 hold · 2 sell (28 analysts)
- Consensus lean
- Hold-leaning
- Consensus price target
- $29.3
- Target vs last price
- +3.6%
What our data shows for PFE
- Our model validated 17 trailing price-to-earnings windows for PFE, built from quarterly earnings records.
- Shares are trading in the upper third of their 12-month price range of $23.67–$29.58.
- The 14-day relative strength index sits at an overbought 73.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for PFE
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent PFE news
TickrTrends' derived news-sentiment signal for PFE is currently leaning positive, computed from recent coverage.
- Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It (zacks.com, 2026-10-20)
TickrTrends take: Pfizer is currently identified as overvalued according to TickrTrends valuation analysis, which suggests the stock price may not reflect underlying fundamentals relative to the Healthcare sector. Given this overvaluation designation, investors focused on valuation metrics should monitor whether upcoming earnings reports or pipeline developments justify the current market price, or whether the stock moves toward more reasonable valuation levels. The trending nature of the stock may be driving price momentum that has outpaced the company's financial fundamentals. - Pfizer vs. AbbVie: Is the Cheaper Pharma Stock Really the Better Investment? (insidermonkey.com, 2026-10-16)
TickrTrends take: Pfizer trades at a valuation that TickrTrends currently assesses as overvalued relative to fundamentals, which makes direct cost comparisons with competitors like AbbVie a relevant analytical exercise for value-conscious investors. The healthcare sector contains significant variation in how individual companies are priced relative to their earnings and assets, so a stock trading at a lower absolute price does not necessarily indicate better valuation. Investors focused on valuation metrics should monitor whether Pfizer's current premium valuation persists or compresses as the company's business performance evolves. - Pfizer (PFE) Pays Out Over 226% of Earnings and Trades at 36.7x Trailing Against 9.8 Forward. What Is the Yield Telling You? (insidermonkey.com, 2026-10-13)
TickrTrends take: Pfizer's dividend payout ratio exceeds its earnings, which typically signals either unsustainable distributions or management confidence in future cash generation, a dynamic worth monitoring alongside its valuation metrics. The company's trailing price-to-earnings multiple substantially exceeds its forward multiple, suggesting the market may be pricing in significant earnings growth or operational improvements ahead. Given TickrTrends' overvalued designation for PFE in the Healthcare sector, investors should track whether the company can narrow the gap between these multiples through actual earnings expansion or if the valuation premium continues to widen.
More PFE news
- Pfizer: The Earnings Test That Matters (NYSE:PFE) (seekingalpha.com, 2026-10-13)
- Pfizer Is Trading at Less Than 10 Times Earnings. But Is the Stock Actually Cheap? (insidermonkey.com, 2026-10-11)
What people are saying
Follow the PFE conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — TickrTrends' derived indicators for PFE showed movement this week as the RSI zone shifted from neutral to overbought territory. The current valuation verdict remains that the stock is overvalued. These technical changes warrant observation by investors monitoring the stock's recent momentum.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — TickrTrends' derived indicators for Pfizer show a quality grade improvement from D to C this week. Despite this upgrade in the quality assessment, the current valuation verdict remains Overvalued. The positive movement in the quality metric suggests some strengthening in underlying fundamentals, though the overvalued status indicates the stock price has not adjusted accordingly.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is PFE stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), PFE is trading at more than a 25% premium to estimated fair value and screens as overvalued. The exact fair value and discount are available to subscribers.
What is PFE's TickrTrends verdict?
PFE's current verdict is Overvalued, refreshed with every weekly Forward Fair Value run.
How does PFE compare to other Healthcare stocks?
PFE ranks #84 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is PFE overbought or oversold?
PFE's 14-day RSI is in the overbought zone on TickrTrends' latest weekly data.
Does PFE pay a dividend?
Yes. PFE paid $1.72 per share over the last twelve months (4 payments), a 6.08% yield on TickrTrends' last price, and has raised the annual total for 15 consecutive years. The next ex-dividend date on file is 2026-11-06.
When does PFE report earnings next?
PFE's next earnings report is scheduled for 2026-11-03 (pre-market), per the published earnings calendar.
Does PFE usually beat earnings estimates?
Over its last 8 reported quarters PFE beat the consensus estimate 8 times and missed 0 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about PFE?
Of 28 analysts covering PFE, 10 rate it a buy, 16 a hold and 2 a sell - hold-leaning, with a consensus price target of $29.3 (+3.6% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Healthcare
Head-to-head comparisons
PFE vs AMGN · PFE vs AZTA · PFE vs BIO · PFE vs CRL · PFE vs DGX